Tiakis Biotech has received positive scientific advice from the US Food and Drug Administration (FDA) for a planned Phase 2 ATHENA clinical trial of tiprelestat in pulmonary arterial hypertension. The therapy has been granted orphan designation in the U.S. and in Europe for pulmonary arterial hypertension.
Dr. Roham Zamanian, Professor of Medicine at Stanford University and Principal Investigator of the ATHENA trial says that “given its unique mechanism of action addressing major pathological processes in pulmonary arterial hypertension, specifically inflammation and BMPR2 deficiency, tiprelestat holds the promise of a disease-modifying therapy.
Read the company press release with further details at this link